Yantai Dongcheng Pharmaceutical Group Co., Ltd (SHE: 002675), a Chinese pharmaceutical company, has announced that it has received approval from the US Food and Drug Administration (FDA) for its radiopharmaceutical 68GaLNC1007. This diagnostic agent targets fibroblast activating protein (FAP) and integrin αvβ3 and is under development to support the treatment of FAP and αVβ3-positive solid tumors.
Preclinical studies and investigator-initiated trials have demonstrated that 68Ga-LNC1007 can significantly enhance tumor uptake, improve tumor targeting efficiency, and optimize pharmacokinetics, all with a favorable safety profile. The molecule may offer superior tumor imaging capabilities in various types of cancer, including lung, breast, renal cell, esophageal, pancreatic, and ovarian cancers. It is anticipated that 68Ga-LNC1007 will be utilized in the diagnostic process for a range of solid tumor types.- Flcube.com
